



COLLÈGE
DE FRANCE
— 1530 —

ORGANIZERS :

Hugues de Thé, Chaire oncologie cellulaire et moléculaire
Alain Fischer, Chaire médecine expérimentale

Cancer and immunity

Thursday 14 and Friday 15 mai 2020
Amphithéâtre Marguerite de Navarre

Thursday 14 mai

- 9h00 Introduction**
Thomas RÖMER, Administrator of Collège de France,
Hugues de THÉ, Alain FISCHER
- 9h15 Pathogenesis**
Riccardo DALLA FAVERA, Columbia University,
New York
Mechanisms of B cell lymphomagenesis
- 9h50** Louis M STAUDT, NIH, Washington DC
Targeted therapy of immune-edited lymphomas
- 10h25** Vishva M DIXIT, Genentech, San Francisco
Why so many ways to die ?
The Non canonical inflammasome pathway
- 11h00 Break**
- 11h20 Metabolism**
Craig B. THOMPSON, MSKCC, New York
The role of cancer metabolism in creating
an immunosuppressive tumor microenvironment
- 11h55 Tumor immunogenicity and T cell responses**
Ton N SCHUMACHER, NCI, Amsterdam
Immunological response of human cancers
to PD-1 blockade
- 12h30 Break**
- 14h00 Tumor immunogenicity and T cell responses
(continued)**
Philippe BOUSSO, Institut Pasteur, Paris
Mechanisms of tumor immunosurveillance
and immunotherapy analyzed at the single cell level
- 14h35** Ido AMIT, Weizmann Institute, Rehovot
The power of ONE : Immunology in age
of single cell genomics
- 15h10 Break**
- 15h40 Tumor microenvironment and immune responses**
Miriam MERAD, Mount Sinai Medical School,
New York
Myeloid cell control of antitumor immunity
- 16h15** Emmanuel DONNADIEU, Institut Cochin, Paris
Imaging of T cell success and failure
in human tumors
- 16h50** Hélène SALMON, Institut Curie, Paris,
Mount Sinai medical School, New York
Contribution of the stromal cell compartment
to tumor immunity

Friday 15 mai

- 9h00** Jérôme GALON, INSERM, Sorbonne Université, Paris
The immune contexture in the era of cancer
immunotherapy
- 9h35 Check point inhibitors**
Tasuku HONJO, Kyoto University : Key note lecture
A new dimension of PD-1 blockade therapy against cancer
- 10h20** Caroline ROBERT, Institut Gustave Roussy, Villejuif
Translational control of cancer immunity
- 10h55 Break**
- 11h25** Laurence ZITVOGEL, Institut Gustave Roussy, Villejuif
The impact of the intestinal microbiota in tumor
immunosurveillance
- 12h00** Éric VIVIER, CIML, Marseille
Harnessing innate immunity in cancer therapy
- 12h35 Break**
- 14h Cellular immunotherapy of cancer**
Michel SADELAIN, MSKCC, New York
How CARs were built and how they work
- 14h35** Carl H JUNE, University of Pennsylvania, Philadelphia
CAR T cell therapies for cancer : progress and challenges
- 15h10** Sébastien AMIGORENA, Institut Curie, Paris
Heterochromatin and anti tumor immunity
- 15h45** Sonia GUEDAN, IDIBAPS, Barcelona
CAR-T cell therapy for solid tumors
- 16h20 Break**
- 16h50** Martine PICCART, Institut Jules Bordet, ULB, Bruxelles
Implementation of innovative immunotherapy of cancer
- 17h30 Conclusions**
Hugues de THÉ and Alain FISCHER

Avec le soutien de :

